Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults

Completed · Early Phase 1

Conditions studied: Receptor Blockade

In brief

Previous research has identified adenosine triphosphate (ATP) as an important vasodilator that is released from red blood cells during exercise and exposure to hypoxic environments in adult humans. Further, older adults appear to have lower blood flow during both of these stressors and also have lower amounts of ATP released from their red blood cells. However, the contribution of ATP to vasodilation in response to exercise and hypoxia is currently unknown due to the lack of an effective ATP receptor antagonist. We aim to determine whether Vitamin B6 or its metabolite, Pyridoxal-5-Phosphate (PLP) is an effective ATP receptor antagonist.

Key facts

Study ID

NCT03738943

Run by

Colorado State University

People needed

9

Starts

2019-02-07

Expected to finish

2021-06-01

Last updated by the study team

2021-07-27

Who can join

Age: 18 and older, up to 30. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Sedentary-moderately active
• Free of chronic disease

You may not qualify if…

• Current smoker
• BMI > 29.9 kg/m2
• Blood pressure equal to or greater than 140/90 mmHg
• Use of any medications including vitamin B6 supplements or antioxidants

Where it is running

• Human Performance and Clinical Research Laboratory — Fort Collins, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.